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Abstract
Background: The 5-year survival rate of the patients with stage I colorectal cancer is about 90 %; therefore,
adjuvant therapy has not been recommended after radical resection; however, about 16–26 % of T2N0M0
patients will be dead at 5 years despite radical curative resection. It indicated that there is a defined group of
patients who are at high risk for relapse or metastasis despite radical operation. This study aimed to find the
patients with T2N0M0 colorectal cancer at high risk for relapse or metastasis.
Methods: From January 1993 to December 2014, 812 patients with histologically confirmed stage T2N0M0
primary colorectal cancer treated by radical surgery with complete clinical follow-up data were eligible for
this study. The medical records of all patients were collected and were retrospectively analyzed. Survival rates
were calculated using Kaplan-Meier method, and survival cures were compared using the log-rank test. Cox
proportional hazards model was used to analyze the significant factors defined in univariate test.
Results: The 5-year and 10-year overall survival rates were 81.9 and 67.7 %, respectively. Male gender, old
age, lymphovascular permeation, perineural invasion, and poor differentiation were associated with low
cancer-specific survival rates in Kaplan-Meier analysis. Multivariate analyses revealed old age, lymphovascular
permeation, perineural invasion, and poor differentiation as significant independent factors predicting worse
prognosis (P < 0.05).
Conclusions: Old age, lymphovascular permeation, perineural invasion, and poor differentiation are risk factors
for the worse prognostic patients with T2N0M0 colorectal patients who would potential benefit from more
aggressive therapy.
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Background
Colorectal cancer has been one of the most common
cancers in the world, especially in developed countries
[1–3]. The incidence and mortality of colorectal cancer
has increased over the past 20 years, and it would in-
crease consecutively if no effective action on colorectal
cancer control. Colorectal cancer was the sixth most
common cancer in China. It was estimated that there
were 274,841 new cases diagnosed in 2010 (157,355 in
males and 117,486 in females), with the crude incidence
rate of 20.1/100,000, highest in males in urban areas.
Age-standardized rates by China standard population of
2000 (ASRcn) and World standard population (Segi’s
population, ASRwld) for incidence were 16.1/100,000
and 15.9/100,000, respectively. There were 132,110 cases
estimated to have died from colorectal cancer in China
in 2010 (76,646 men and 55,464 women) with the crude
mortality rate of 10.1/100,000. The ASRcn and ASRwld
for mortality were 7.55/100,000 and 7.44/100,000,
respectively, higher in males and urban areas than in
females and rural areas [4].
Approximately one tenth of colorectal cancer patients
present with stage I disease. For these patients, the 5-
year survival rate is about 90 %; therefore, adjuvant ther-
apy has not been recommended after radical resection;
however, about 16–26 % of T2N0M0 patients will be
dead at 5 years despite radical curative resection [5, 6].
Furthermore, a nested reverse transcriptase-polymerase
chain reaction was used to detect the circulating tumor
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cell by using CEA as tumor cell marker. The positive
rate in patients with Dukes A was 38 %. It indicated that
there is a defined group of patients who are at high risk
for relapse despite radical operation [7].
To identify a subset of patients at high risk for recur-
rence and tumor-related mortality, we have evaluated
treatment results and prognostic factors for patients with
T2N0M0 colorectal cancer treated by radical resection.
Methods
From January 1993 to December 2014, patients with his-
tologically confirmed stage T2N0M0 primary colorectal
cancer treated by radical surgery in Tianjin Union Medical
Center were eligible for this study. The medical records of
all patients were collected and were retrospectively ana-
lyzed. Because chemoradiotherapy may affect the number
of lymph nodes and the metastatic pattern [8], patients
with colorectal cancer undergoing neoadjuvant therapy
were excluded. The study protocol was approved by the
local ethics committee (Research ethics committee of
Tianjin Union Medical Center).
The preoperative blood test included the level of CEA
and CA19-9. All patients underwent a radical operation.
The specimens were examined for tumor invasive depth,
macroscopic type, tumor diameter, histological type, differ-
entiation, number of involved lymph nodes, lymphovascu-
lar invasion, and perineural invasion. The specimens were
staged according to the AJCC and UICC system (2010)
after the final histopathological examination. The patients
were followed at 3-month interval for 2 years, at 6-month
interval for the next 3 years, thereafter yearly. Follow-up
was history, physical examination, serum carcinoembryonic
antigen and CA19-9 assay, chest X-ray, liver ultrasound,
and abdominopelvic computed tomography, as possible.
Surveillance colonoscopy was performed annually.
Statistical analysis was conducted using SPSS software
(SPSS for windows version 17.0, Chicago, IL). Survival
rates were calculated using Kaplan-Meier method, and
survival cures were compared using the log-rank test.
Cox proportional hazards model was used to analyze the
significant factors defined in univariate test. Significant
independent factors for overall survival were defined.
Chi-square analysis and t test were used to comparing
factors between different groups. A P value less than
0.05 was considered statistically significant.
Results
Patient characteristics and pathologic variables
The clinical characteristics and pathologic variables of the
812 patients with complete clinical follow-up data for
analysis are summarized in Table 1. The median age was
60 years (range, 24–88 years). The operations underwent
on all patients were with curative intent including right
colectomy (4.7 %, 38/812), extended right colectomy (0.2
%, 2/812), left colectomy (1.7 %, 14/812), sigmoid colec-
tomy (3.9 %, 36/812), total colectomy, abdominoperineal
resection (51.1 %, 415/812), Dixon operation (36.3 %, 295/
812), and Harrtmann (0.2 %, 2/812) operation (1.2 %, 16/
812). All reported margins were negative for tumor
involvement. The median tumor diameter was 30 mm
(range, 5–70 mm). During the follow-up period of
130 months (range, 6–234 months), the 5- and 10-year
overall survival rates were 81.9 and 67.7 %, respectively.
Univariate analyses
Univariate analyses of factors affecting survival are list in
Table 1. Using Kaplan-Meier analysis for overall survival
rate, we found that male gender, old age, lymphovascular
permeation, perineural invasion, and poor differentiation
were associated with low cancer-specific survival rates
(P < 0.05). However, no statistically significant difference
regarding depth of tumor invasion, bowel obstruction,
colorectal tumor locations, preoperative serum CEA
level, and CA19-9 level were observed (P > 0.05).
Multivariate analyses
A Cox multiple regression model was used to assess the
influence of all significant covariates on survival. In the
proportional hazards model analysis, old age, lympho-
vascular permeation, perineural invasion, and poor
differentiation were significant independent factors
predicting worse prognosis (P < 0.05) (Table 2).
Discussion
Colorectal cancer is one of the most commonly diagnosed
cancers in the world. Over the last decade, total morbidity
and mortality rates of colorectal cancer are increasing
steadily in Asia countries, especially in China, colorectal
cancer has become a fatal disease. T2N0M0 colorectal
cancers are usually considered less advanced and are usu-
ally associated with favorable prognosis. However, once
the tumor invades through the muscularis mucosa, metas-
tasis to distant organs can occur. And moreover, in this
study, the 10-year overall survival rate was 67.7 % despite
radical resection. The Swedish Rectal Cancer Trial showed
a significant reduction in LR in stage I patients with pre-
operative pelvic radiation, from 12 to 4 % [9].Indiscrimin-
ate use is not recommended in the early-stage patients
owing to the over treatment of the majority, although
adjuvant therapy may clearly benefit some of this popula-
tion. Our study’s primary objective was to find a high-risk
group of T2N0M0 patients using routine clinical and
pathologic factors so that the salutary effects of adjuvant
therapy might be extended to the patients.
Tumor differentiation is one of common pathologic vari-
ables. In our study, patients with poorly differentiated tu-
mors also fared worse. Poorly differentiated tumors have a
worse prognosis compared with better differentiated ones
Xu et al. World Journal of Surgical Oncology  (2016) 14:76 Page 2 of 6
[10].Poorly differentiated colorectal cancers has been
shown to correlate with bowel penetration, lymph node
involvement, and vascular invasion, indicating that it is a
risk factor for dissemination of colorectal cancer [11].
Other clinical studies have demonstrated that patients with
poorly differentiated cancers have worse prognosis [12, 13].
Our results indicate that lymphovascular permeation
has been linked with poor prognosis. Lymphovascular
invasion can occur intramurally within colorectal wall it-
self or in the surrounding tissue. Although arterial inva-
sion occurs, most series define and describe vascular
invasion based on venous invasion. Venous invasion in
Table 1 Univariate analyses of factors for overall survival (OS)
Number (%) 5-year OS (%) 10-year OS (%) χ2 P
Gender
Male 435 (53.6) 77.0 63.9 6.379 0.012
Female 377 (46.4) 86.4 71.1
Age (years)
≤35 32 (4.0) 84.0 80.6 45.128 0.000
36–64 470 (57.9) 82.1 76.0
≥65 310 (38.2) 72.2 49.6
Depth of tumor invasion
Superficial muscle 320 (39.4) 82.7 67.6 2.071 0.156
Deep muscle 492 (60.6) 80.3 65.7
Lymphovascular permeation
Positive 60 (7.4) 69.2 50.4 11.075 0.001
Negative 752 (92.6.) 83.5 69.5
Perineural invasion
Positive 31 (3.8) 68.2 54.6 7.769 0.005
Negative 781 (96.2.) 83.1 68.4
Differentiation
Well 207 (25.5) 86.7 73.7 15.509 0.000
Moderate 456 (56.2) 81.7 66.7
Poor 135 (16.6) 71.1 48.5
Mucinous 14 (1.7) 67.7 14.3
Bowel obstruction
Yes 90 (1.7) 81.7 68.9 1.06 0.304
No 722 (1.7) 83.5 70.0
Location
Colon 183 (11.1) 86.5 73.6 1.56 0.212
Rectum 629 (88.9) 80.3 65.6
Preoperative CEA level(ng/ml)
<5 299 (36.8) 82.0 66.8 0.583 0.747
≥5 513 (63.2) 81.2 67.7
Preoperative CA19-9 level(ng/ml)
<37 643 (79.2) 81.6 67.8 1.92 0.383
≥37 169 (20.8) 82.1 63.3
Table 2 Multivariate analyses of risk factors for overall survival (OS)
Variables β SE Wald P Exp(β)
Differentiation 0.53 0.122 18.889 0.000 1.689
Perineural invasion 1.061 0.308 11.871 0.01 2.888
Lymphovascular permeation 0.932 0.244 14.559 0.02 2.541
Age 0.831 0.143 34.026 0.000 2.294
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colon cancer occurs in 42 % of patients and increases
with increasing grade and stage [14]. Iinuma et al. [15]
found venous invasions significantly correlated with the
presence of isolated tumor cells in blood samples. Fur-
thermore, another study reported that detecting circulat-
ing tumor cells in the peripheral blood was as a useful
tool for determining the patients at high risk for recur-
rence [16]. These studies support the hypothesis that
venous invasion is an essential step in the process of
hematogenous metastasis. Patients with blood vessel in-
vasion had a 74 % survival compared to those without it
at 85 %. In those patients with both intramural and
extramural vascular invasion, the prognosis was even
worse at 32 %. Lymphatic invasion is the most common
mechanism leading to metastatic disease. Lymphatic
exist within the colorectal wall and lymphatic invasion
correlates with the depth of penetration of colon can-
cers. T2 tumors have a risk of lymph node involvement
up to 25 %. The presence of lymphovascular permeation
was the only independent factor associated with a higher
incidence of lymph node metastasis on multivariate ana-
lysis (odds ratio 1.48, 95 % CI 1.44–13.47, P = 0.009)
[17]. The lymphatic drainage goes along the venous
drainage of the colon and rectum, ultimately coursing
through the portal vein and into the liver. Metastatic
liver disease is felt to occur typically due to lymphatic
spread. Furthermore, vascular invasion and vascular
endothelial growth factor overexpression were all con-
siderably correlated to the higher postoperative relapse
rate and poorer overall survival rates in colorectal cancer
patients after curative resection [18, 19].
Perineural invasion (PNI) is a pathologic process char-
acterized by tumor invasion of nervous structures and
spread along nerve sheaths. The pathogenesis of PNI
likely involves complex signaling between tumor cells,
the nerves, and stromal cells, but this area of research is
still largely in its infancy [20–23]. PNI is known as a
marker for a more aggressive tumor phenotype and poor
prognosis in several malignancies, most notably head
and neck and prostate cancers [24–28]. Perineural inva-
sion also increases with increasing grade and stage of
the tumor. It occurs in 14–32 % of colorectal cancers
and can extend to as far as 10 cm from the primary
tumor. Numerous studies have confirmed poorer prog-
nosis when perineural invasion is noted.
Liebig et al. [23] found that disease-free and overall
survival rates were significantly affected by PNI status
independent of tumor stage in colorectal patients.
Among node-negative patients, the 5-year disease-free
survival for PNI-negative patients was almost three-fold
greater than for PNI positive patients (82 vs. 29 %, re-
spectively). In fact, node-negative patients with PNI had
a significantly worse disease-free survival rate than
node-positive patients (29 vs. 56 %). Similar results were
seen for overall survival, where the 5-year overall sur-
vival for node-negative patients with PNI positive tu-
mors was 43 % compared with 87 % for patients with
PNI negative tumors. Similarly, node-negative but PNI-
positive patients had a significantly lower 5-year overall
survival rate compared with node-positive patients (43
vs. 67 %). A meta-analysis indicated that PNI was a poor
prognostic factor in CRC patients, and the postoperative
survival of stage II CRC patients with PNI(+) was prob-
ably more similar to that of stage III patients [29].
Younger age is a positive prognostic factor for patients
with colorectal cancer [30–32]. In this study, younger pa-
tients were found to have better overall survival both in
the univariate and multivariate analysis. Previous studies
found that younger patients had worse prognosis [33], be-
cause younger patients were found to have more locally
advanced, higher stage, and less favorable histologic sub-
types tumors than older patients at the time of diagnosis
[34–38]. It is not clear why younger patients tend to
present with more advanced disease. Perhaps, because of
their young age, physicians are less likely to suspect malig-
nant disease than in older patients, thus leading to a delay
in appropriate investigations and diagnosis. Another po-
tential explanation is that younger patients would gener-
ally not to be included in CRC screening initiatives and
would be less likely to have early cancers diagnosed
through these screening initiatives. Furthermore, younger
patients were treated more aggressively. This may partly
explain their improved prognosis. In recent studies, when
controlling for tumor stage, patient, and treatment factors,
young patients had a superior overall survival [39–41].
The relationship between survival after surgical resec-
tion of colorectal carcinoma and perioperative blood
transfusion was studied in many researches. Periopera-
tive blood transfusion could impact immune function,
increased postoperative mortality, local recurrence rate,
and distant metastasis rate in colorectal cancer patients
[42]. The combination of perioperative blood transfusion
and subsequent development of postoperative infectious
complications may be associated with a poor prognosis
[43]. In our study, there were only six blood transfused
patients, so we could not analyze further.
Conclusions
In conclusion, poor differentiation, old age, lymphovas-
cular permeation, and perineural invasion are associated
with high risk for recurrence or metastasis in patients
with T2N0M0 colorectal caner. Through the evaluation
of routine clinical and pathologic data for patients
treated with curative surgery, this study has defined a
subpopulation of patients with T2N0M0 colorectal can-
cer that are at increased risk of mortality. These findings
could identify patients with T2N0M0 colorectal cancer
who might benefit from more aggressive therapy.
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